These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9086340)
1. Placental protein 14 (PP14) does not predict endometrial status under hormone replacement therapy. Haenggi W; Bersinger NA; Altermatt HJ; Birkhaeuser MH Gynecol Endocrinol; 1997 Feb; 11(1):51-7. PubMed ID: 9086340 [TBL] [Abstract][Full Text] [Related]
2. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Hänggi W; Bersinger N; Altermatt HJ; Birkhäuser MH Maturitas; 1997 Jun; 27(2):133-43. PubMed ID: 9255748 [TBL] [Abstract][Full Text] [Related]
3. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy. Okon MA; Lee S; Laird SM; Li TC Hum Reprod; 1998 Aug; 13(8):2261-5. PubMed ID: 9756307 [TBL] [Abstract][Full Text] [Related]
4. A prospective randomized controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology. Okon MA; Lee S; Laird SM; Li TC Hum Reprod; 2001 Jun; 16(6):1244-50. PubMed ID: 11387299 [TBL] [Abstract][Full Text] [Related]
5. Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapy. Byrjalsen I; Thormann L; Meinecke B; Riis BJ; Christiansen C Hum Reprod; 1992 Sep; 7(8):1042-7. PubMed ID: 1400926 [TBL] [Abstract][Full Text] [Related]
6. Serum placental protein 14: a novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium. Tankó LB; Warming L; Bagger YZ; Byrjalsen I; Jensen S; Christiansen C Biomarkers; 2002; 7(3):257-66. PubMed ID: 12141068 [TBL] [Abstract][Full Text] [Related]
7. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Foster RH; Balfour JA Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560 [TBL] [Abstract][Full Text] [Related]
8. Clinical applications of serum placental protein 14 (PP14) measurement in the IVF-ET cycle. Suzuki Y; Sugiyama R; Fukumine N; Usuda S; Itoh H; Isaka K; Takayama M; Teisner B J Obstet Gynaecol Res; 2000 Aug; 26(4):295-302. PubMed ID: 11049241 [TBL] [Abstract][Full Text] [Related]
9. The measurement of secretory endometrial protein PP14 in serum from postmenopausal women receiving unopposed estrogen or continuously combined estrogen/progestogen. Byrjalsen I; Riis BJ; Christiansen C Gynecol Endocrinol; 1989 Jun; 3(2):143-52. PubMed ID: 2816479 [TBL] [Abstract][Full Text] [Related]
10. Circulating concentrations of placenta protein 14 during the natural menstrual cycle in women significantly reflect endometrial receptivity to implantation and pregnancy during successive assisted reproduction cycles. Westergaard LG; Wiberg N; Andersen CY; Laursen SB; Kliem A; Westergaard JG; Teisner B Hum Reprod; 1998 Sep; 13(9):2612-9. PubMed ID: 9806294 [TBL] [Abstract][Full Text] [Related]
11. The post-menopausal uterus: the effect of hormone replacement therapy on the serum levels of secretory endometrial protein PP14/beta-lactoglobulin homologue. Seppälä M; Alfthan H; Vartiainen E; Stenman UH Hum Reprod; 1987 Nov; 2(8):741-3. PubMed ID: 2830296 [TBL] [Abstract][Full Text] [Related]
12. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Boerrigter PJ; van de Weijer PH; Baak JP; Fox H; Haspels AA; Kenemans P Maturitas; 1996 May; 24(1-2):63-71. PubMed ID: 8794436 [TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of two endometrial proteins are not useful for monitoring postmenopausal estrogen/progesterone therapy. Ren SG; Braunstein GD; Cedars M; Gambone J; Judd H Fertil Steril; 1990 Sep; 54(3):532-4. PubMed ID: 1697814 [TBL] [Abstract][Full Text] [Related]
14. Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Byrjalsen I; Bjarnason NH; Christiansen C Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):539-49. PubMed ID: 10076125 [TBL] [Abstract][Full Text] [Related]
15. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347 [TBL] [Abstract][Full Text] [Related]
16. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. Johannisson E; Holinka CF; Arrenbrecht S Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386 [TBL] [Abstract][Full Text] [Related]
17. Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: correlation with serum hormone concentrations and bleeding patterns. Byrjalsen I; Thormann L; Riis BJ; Christiansen C Maturitas; 1992 Aug; 15(1):39-46. PubMed ID: 1388220 [TBL] [Abstract][Full Text] [Related]
18. Serum placental protein 14 in pre-menopausal and post-menopausal women--dependency on oestrogen/progestogen status. Byrjalsen I; Riis BJ; Christiansen C Maturitas; 1990 Jun; 12(2):79-88. PubMed ID: 2255265 [TBL] [Abstract][Full Text] [Related]
19. Is the measurement of placental protein-14 and CA-125 in plasma and uterine flushings useful in the evaluation of peri-menopausal and post-menopausal bleeding? Li TC; Okon MA; Dalton CF; Heatley M; Laird SM Hum Reprod; 1998 Oct; 13(1O):2895-901. PubMed ID: 9804252 [TBL] [Abstract][Full Text] [Related]
20. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Byrjalsen I; Thormann L; Meinecke B; Riis BJ; Christiansen C Obstet Gynecol; 1992 Apr; 79(4):523-8. PubMed ID: 1532445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]